Adoption of Pharmacogenomic Testing: A Marketing Perspective.
awareness
genetic testing services
innovation
marketing strategies
patients
personalized medicine
pharmacogenomics
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
06
2021
accepted:
01
09
2021
entrez:
4
10
2021
pubmed:
5
10
2021
medline:
5
10
2021
Statut:
epublish
Résumé
Pharmacogenomics is becoming an important part of clinical practice and it is considered one of the basic pillars of personalised medicine. However, the rate of pharmacogenomics adoption is still low in many healthcare systems, especially in low- or middle-income countries. The low level of awareness of healthcare specialists could be a potential reason due to which pharmacogenomics application is still in a premature stage but there are several other barriers that impede the aforementioned process, including the lack of the proper promotion of pharmacogenomic testing among interested stakeholders, such as healthcare professionals and biomedical scientists. In this study, we outline the available marketing theories and innovation that are applied to personalized medicine interventions that would catalyze the adoption of pharmacogenomic testing services in clinical practice. We also present the current ethical and legal framework about genomic data and propose ways to tackle the main concerns mentioned in the literature and to improve the marketing perspective of PGx.
Identifiants
pubmed: 34603034
doi: 10.3389/fphar.2021.724311
pii: 724311
pmc: PMC8484788
doi:
Types de publication
Journal Article
Langues
eng
Pagination
724311Informations de copyright
Copyright © 2021 Koufaki, Karamperis, Vitsa, Vasileiou, Patrinos and Mitropoulou.
Déclaration de conflit d'intérêts
Authors KK and CM were employed by the company The Golden Helix Foundation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Med Genomics. 2018 Oct 26;11(1):94
pubmed: 30367635
BMJ Open. 2011 Jul 29;1(1):e000110
pubmed: 22021765
Nat Rev Genet. 2011 Dec 13;13(2):146; author reply 146
pubmed: 22158309
Pharmgenomics Pers Med. 2017 Dec 05;10:279-285
pubmed: 29255371
Ghana Med J. 2015 Mar;49(1):50-6
pubmed: 26339085
Pharmgenomics Pers Med. 2019 Oct 07;12:247-255
pubmed: 31632127
Per Med. 2020 Jul 1;17(4):251-260
pubmed: 32589096
JMIR Mhealth Uhealth. 2020 Jul 6;8(7):e18072
pubmed: 32442132
JCO Oncol Pract. 2020 Dec;16(12):799-800
pubmed: 33301699
Clin Pharmacol Ther. 2018 May;103(5):752-755
pubmed: 29417560
BMC Med Genomics. 2018 Feb 13;11(1):18
pubmed: 29433521
Am J Pharm Educ. 2010 Feb 10;74(1):7
pubmed: 20221358
Clin Genet. 2012 Oct;82(4):388-94
pubmed: 22698141
Pharmacogenomics. 2016 Apr;17(5):455-8
pubmed: 27027537
Per Med. 2014 Jan;11(1):15-26
pubmed: 29751393
Pharmacy (Basel). 2017 Jun 30;5(3):
pubmed: 28970448
J Pers Med. 2020 Sep 18;10(3):
pubmed: 32962013
Clin Pharmacol Ther. 2017 Nov;102(5):739-741
pubmed: 28581028
J Pers Med. 2020 Oct 24;10(4):
pubmed: 33114420
Risk Manag Healthc Policy. 2020 Aug 21;13:1279-1291
pubmed: 32904476
Pharmacogenet Genomics. 2020 Jun;30(4):73-80
pubmed: 32187156
J Neural Transm (Vienna). 2017 Jan;124(1):25-32
pubmed: 26645377
Am J Hum Genet. 2020 Oct 1;107(4):589-595
pubmed: 33007198
Cell Tissue Bank. 2011 May;12(2):71-80
pubmed: 20012777
J Pharm Sci. 2017 Sep;106(9):2368-2379
pubmed: 28619604
EMBO Rep. 2014 May;15(5):472-6
pubmed: 24723683
J Eval Clin Pract. 2015 Aug;21(4):703-9
pubmed: 25929423